Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Celmatix, a biotechnology company focused on helping physicians guide patients to treatments that maximize their personal reproductive potential, has announced six research presentations at the annual meeting of the American Society for Reproductive Medicine (ASRM), held in Boston.
Among the data presented was a new study suggesting that up to 25 percent of patients may be discontinuing assisted reproductive therapies such as in vitro fertilization (IVF) early, while they still have a good chance of having a baby.
The clinical study, which was performed on a dataset of over 6,000 patients from study coauthors Reproductive Medicine Associates of New York, showed that 68 percent of women conceived within two cycles. For those who did not conceive in that time frame and chose to discontinue treatment, the data suggested that more than half (60 percent) would have become pregnant if they had proceeded with an additional two treatment cycles.
Other Celmatix findings presented at ASRM include data on genetic markers related to currently unexplained female infertility and IVF success; factors correlated with higher risk of ectopic pregnancy; and an analytical model that predicts the estimated number of cycles needed by a particular couple to achieve live birth using various fertility treatments.
"We are excited to have this opportunity to present our research findings at ASRM, especially our finding that most patients who are initially unsuccessful with fertility treatments still have a significant chance of having a baby," said Piraye Yurttas Beim, PhD, Founder and Chief Executive Officer of Celmatix. "There are so many unanswered questions about why some women struggle with fertility. These questions create difficult decisions for women and their healthcare providers. Our goal is to offer tools and resources that make this process as informed and evidencebased as possible."
The oral abstracts presented by Celmatix were:
The three poster presentations were:
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Fertility category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Inc., Celmatix. "Women may be stopping IVF treatment prematurely." Medical News Today. MediLexicon, Intl., 21 Oct. 2013. Web.
13 Dec. 2013. <http://www.medicalnewstoday.com/releases/267642>
Inc., C. (2013, October 21). "Women may be stopping IVF treatment prematurely." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267642.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.